These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 21743497)
1. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497 [TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines. Zhao R; Quaroni L; Casson AG J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1192-9. PubMed ID: 22980068 [TBL] [Abstract][Full Text] [Related]
3. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050 [TBL] [Abstract][Full Text] [Related]
4. The Wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. Cai C; Zhu X Mol Med Rep; 2012 May; 5(5):1191-6. PubMed ID: 22367735 [TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986 [TBL] [Abstract][Full Text] [Related]
6. A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Tang KH; Dai YD; Tong M; Chan YP; Kwan PS; Fu L; Qin YR; Tsao SW; Lung HL; Lung ML; Tong DK; Law S; Chan KW; Ma S; Guan XY Cancer Res; 2013 Apr; 73(7):2322-32. PubMed ID: 23382045 [TBL] [Abstract][Full Text] [Related]
7. The in-vitro spheroid culture induces a more highly differentiated but tumorigenic population from melanoma cell lines. Mo J; Sun B; Zhao X; Gu Q; Dong X; Liu Z; Ma Y; Zhao N; Liu Y; Chi J; Sun R Melanoma Res; 2013 Aug; 23(4):254-63. PubMed ID: 23752306 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells. Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894 [TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer. Yue D; Zhang Z; Li J; Chen X; Ping Y; Liu S; Shi X; Li L; Wang L; Huang L; Zhang B; Sun Y; Zhang Y Exp Cell Res; 2015 Aug; 336(1):141-9. PubMed ID: 26096658 [TBL] [Abstract][Full Text] [Related]
10. Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. Chen WC; Hsu HP; Li CY; Yang YJ; Hung YH; Cho CY; Wang CY; Weng TY; Lai MD Int J Oncol; 2016 Nov; 49(5):1881-1889. PubMed ID: 27633757 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667 [TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Barok M; Tanner M; Köninki K; Isola J Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915 [TBL] [Abstract][Full Text] [Related]
13. Significance of CD90+ cancer stem cells in human liver cancer. Yang ZF; Ho DW; Ng MN; Lau CK; Yu WC; Ngai P; Chu PW; Lam CT; Poon RT; Fan ST Cancer Cell; 2008 Feb; 13(2):153-66. PubMed ID: 18242515 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648 [TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Nishikawa S; Konno M; Hamabe A; Hasegawa S; Kano Y; Ohta K; Fukusumi T; Sakai D; Kudo T; Haraguchi N; Satoh T; Takiguchi S; Mori M; Doki Y; Ishii H Int J Oncol; 2013 Apr; 42(4):1437-42. PubMed ID: 23440340 [TBL] [Abstract][Full Text] [Related]
16. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254 [TBL] [Abstract][Full Text] [Related]
17. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916 [TBL] [Abstract][Full Text] [Related]
18. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Lobba AR; Forni MF; Carreira AC; Sogayar MC Cytometry A; 2012 Dec; 81(12):1084-91. PubMed ID: 23090904 [TBL] [Abstract][Full Text] [Related]
20. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Yan X; Luo H; Zhou X; Zhu B; Wang Y; Bian X Oncol Rep; 2013 Dec; 30(6):2733-40. PubMed ID: 24101104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]